Erec Stebbins
Founder
Panosome
Panosome utilizes a proprietary VAST platform based on the African Trypanosome surface array to generate antibodies against challenging targets like small molecules, peptides, and proteins. This technology allows for the attachment of diverse antigens to a highly immunogenic coat, yielding superior antibody titers compared to traditional methods. The company focuses on developing novel research, diagnostic, and therapeutic products for targets previously considered intractable.
Updated 7 months ago
Funding
Raised to date
$3.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
EVGCKI
$2M · Grant
Announced May 2024
Disclosed cumulative: $3.6M
2/2
RoundDateAmountValuationInvestors
Founders
Joey Verdi
Founder
Nina Papavasiliou
Founder
Product
Problem
Traditional antibody generation platforms struggle to produce antibodies against challenging targets such as small molecules, peptides, and certain proteins. This limitation hinders the development of novel immunotherapies and diagnostics for diseases that are currently difficult to treat.
Solution
Panosome has developed the VAST (VSG-immunogen Array by Sortase Tagging) platform, a novel approach to antibody generation that leverages the highly immunogenic surface of the African trypanosome. This platform allows for the covalent attachment of a wide array of antigens, including small molecules, peptides, and proteins, to a densely packed array of over ten million Variant Surface Glycoprotein (VSG) proteins. This system significantly enhances antibody titers and efficacy compared to conventional methods. The VAST platform is particularly effective for targets that have historically proven intractable for standard antibody production.
Target Audience
The primary customers are pharmaceutical companies and research institutions seeking to develop antibodies against challenging targets for therapeutic and diagnostic applications.
Features
- VAST platform utilizes the African trypanosome's Variant Surface Glycoprotein (VSG) coat for antigen display.
- Antigens are covalently attached to VSG proteins via sortase tagging, enabling a broad range of target molecules.
- Capable of generating antibodies against small molecules, peptides, proteins, carbohydrates, and lipids.
- Employs a "Hyper Speed" bioinformatic pipeline for accelerated selection of high-affinity antibodies.
- Integrates single B-cell sorting with transcriptome analysis to identify potent antibody sequences.
- Demonstrated success in generating picomolar affinity antibodies for therapeutic applications, such as anti-fentanyl antibodies.
- Platform is adaptable for research, diagnostic, and therapeutic antibody development.